Development of a new carvedilol tablet with rapid onset of action

American Journal of Drug Discovery and Development

Volumn 2, Issue 2, 2012, Pages 55-71

  Makky, Amna M A ^a   Ahmed, Iman S ^a,b   El Nabarawi, Mohamed A ^a   El Moneim, Rehab A Abd ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b UNIVERSITY OF SHARJAH   (United Arab Emirates)

^c 6th of October City   (Egypt)

Author keywords

2 3 factorial design; Anti hypertensive activity; Carvedilol; Freeze dried tablets; Solid hspersions

Indexed keywords

CARVEDILOL; CARVEPRESS; GELATIN; GLYCINE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOMECHANICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; FREEZE DRYING; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MECHANICAL STRENGTH; NONHUMAN; POWDER; RAT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TABLET DISINTEGRATION TIME; TABLET FORMULATION; TABLET FRIABILITY;

EID: 84856865114     PISSN: 2150427X     EISSN: 21504296     Source Type: Journal    
DOI: 10.3923/ajdd.2012.55.71     Document Type: Article

References (30)

1. Abdelbary, G., C. Eouani, P. Prinderre, J. Joachim, J. Reynier and P. Piccerelle, 2005. Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration. Int. J. Pharm., 292: 29-41.
2. Ahmed, I.S. and M.H. Aboul-Einien, 2007. In vit. a. in vi. evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin. Eur. J. Pharm. Sci., 32: 58-68.
3. Al-Rejaie, S.S., 2009. Inhibition of ethanol-induced gastric mucosal damage by carvedilol in male wistar albino rats: Possible biochemical changes. Int. J. Pharmacol., 5: 146-154.
4. Amer, M., 1977. Mechanism of action of β-blockers in hypertension. Biochem. Pharmacol., 26: 171-175.
5. Amidon, G.L., H. Lennernaes, V.P. Shah and J.R. Crison, 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation. in vit. drug product dissolution a. in vi. bioavailability. Pharm. Res., 12: 413-420.
6. Badawi, A.A., M.A. El-Nabarawi, D.A. El-Setouhy and S.A. Alsammit, 2011. Characterization and stability testing of itraconazole solid dispersions containing crystallization inhibitors. Am. J. Drug Discovery Dev., 1: 144-159.
7. Balamuralidhara, V., T.M. Pramodkumar, N. Srujana, M.P. Venkatesh, N.V. Gupta, K.L. Krishna and H.V. Gangadharappa, 2011. pH sensitive drug delivery systems: A review. Am. J. Drug Discovery Dev., 1: 24-48.
8. Balamuralidhara, V., S.A. Sreenivas, H.V. Gangadharappa and T.M. Pramodkumar, 2009. Investigation on the effect of different disintegrants on the orodispersible tablets of rabeprazole. Asian J. Scientific Res., 2: 190-197.
9. Council of Europe, 2000. European Pharmacopoeia. 5th Edn., Directorate for the Quality of Medicines, Council of Europe, Strasbourg, France.
10. Djagny, V.B., Z. Wang and S. Xu, 2001. Gelatin: A valuable protein for food and pharmaceutical industries. Crit. Rev. Food Sci. Nutr., 41: 481-492.
11. Frishman, W.H., 1998. Carvedilol. N. Engl. J. Med., 339: 1759-1765.
12. Giessmann, T., C. Modess, U. Hecker, M. Zschiesche and P. Daze. et al., 2004. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects*CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin. Pharmacol. Ther., 75: 213-222.
13. Jun, T. and A. Wennmalm, 1994. NO-dependent and-independent elevation of plasma levels of insulin and glucose in rats by L-arginine. Br. J. Pharmacol., 113: 345-348.
14. Kasim, N.A., M. Whitehouse, C. Ramachandran, M. Bermejo and H. Lennern. et al., 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm., 1: 85-96.
15. Khan, G.M. and J.B. Zhu, 2001. Controlled release coprecipitates of ibuprofen and carbopol® 934p-NF: Preparation, characterization a. in vit. drug release. J. Medical Sci., 1: 355-360.
16. Khan, G.M., 2001. Controlled release oral dosage forms: Some recent advances in matrix type drug delivery systems. J. Medical Sci., 1: 350-354.
17. Khan, G.M., F. Wazir and J.B. Zhu, 2001. Ibuprofen-cyclodextrin inclusion complexes: Evaluation of different complexation methods. J. Medical Sci., 1: 193-199.
18. Mahmoud, E.A., E.R. Bendas and M.I. Mohamed, 2009. Preparation and evaluation of self-nanoemulsifying tablets of carvedilol. AAPS PharmSciTech., 10: 183-192.
19. Sabar, M.H., L.H. Samein and H.B. Sahib, 2011. Some variables affecting the formulation of ketoprofen sustained release oral tablet using polyelectrolyte complex as a matrix former. J. Pharm. Allied Health Sci., 1: 1-15.
20. Shaheen, S.M., M.N. Hossen, K.M. Islam, M. Ahmed, M.S. Amran and M. Rashid, 2006. Effect of bio-adhesive polymers like HPMC, gelatin, Na-CMC and xanthan gum on theophylline release from respective tablets. Int. J. Pharmacol., 2: 504-508.
21. Shoukri, R.A., I.S. Ahmed and R.N. Shamm, 2009. In vit. a. in vi. evaluation of nimesulide lyophilized orally disintegrating tablets. Eur. J. Pharm. Biopharm., 73: 162-171.
22. Sinswat, P., X. Gao, M.J. Yacaman, R.O. Williams and K.P. Johnston, 2005. Stabilizer choice for rapid dissolving high potency itraconazole particles formed by evaporative precipitation into aqueous solution. Int. J. Pharm., 302: 113-124.
23. Smith, J.C., G. Tarocco, F. Merazzi and U. Salzmann, 2006. Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation? Curr. Med. Res. Opin., 22: 709-720.
24. Talbert, R.L., 2004. Pharmacokinetics and pharmacodynamics of β blockers in heart failure. Heart Fail. Rev., 9: 131-137.
25. Tanaka, M., H. Masumura, S. Tanaka and A. Akashi, 1987. Studies on the antihypertensive properties of carvedilol, a compound with β-blocking and vasodilating effects. J. Cardiovasc. Pharmacol., 10: S52-S57.
26. Topaloglua, Y., G. Yenerb and U. Gonullu, 1999. Inclusion of ketoprofen with skimmed milk by freeze-drying. Il Farmaco, 54: 648-652.
27. Ubaidulla, U., M.V.S. Reddy, K. Ruckmani, F.J. Ahmad and R.K. Khar, 2007. Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix. in vit. a. in vi. characteristics. AAPS PharmSciTech., 8: E13-E20.
28. Van Drooge, D.J., W.L. Hinrichs and H.W. Frijlink, 2004. Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and ternary butyl alcohol as solvent. J. Pharm. Sci., 93: 713-725.
29. Vishnu, Y.V., K. Chandrasekhar, G. Ramesh and Y.M. Rao, 2007. Development of mucoadhesive patches for buccal administration of carvedilol. Curr. Drug Deliv., 4: 27-39.
30. Zhao, J.H., J.H. Fu, S.M. Wang, C.H. Su and Y. Sh. et al., 2007. A novel transdermal patch incorporating isosorbide dinitrate with bisoprolo. In vit. a. in vi. characterization. Int. J. Pharm., 337: 88-101.